NEW YORK (GenomeWeb News) – Oxford Nanopore Technologies said today in its annual report that a commercialization agreement it had with Illumina will terminate on June 30, 2016.

The decision is the outcome of an arbitration demand that Illumina brought against Oxford Nanopore in 2011 over the terms of the agreement. The two firms dismissed the suit in April and agreed to amend the commercialization deal, according to Oxford's annual report.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.